戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 l gastrointestinal disorders such as IBS and functional dyspepsia.
2 cer and 9 sex- and age-matched patients with functional dyspepsia.
3 inear mixed models, controlling for comorbid functional dyspepsia.
4 phageal squamous epithelium of patients with functional dyspepsia.
5 wel syndrome (IBS) and 23 (28.8%) had one of functional dyspepsia.
6 ion may be implicated in the pathogenesis of functional dyspepsia.
7 s, 722 (49.7%) met the Rome III criteria for functional dyspepsia.
8 antly for any of the diagnostic criteria for functional dyspepsia.
9 ts had peptic ulcer and 56 were diagnosed as functional dyspepsia.
10 prandial stomach distention in patients with functional dyspepsia.
11 ty of meal-related symptoms in patients with functional dyspepsia.
12  gastric accommodation, is also effective in functional dyspepsia.
13 c antidepressant therapy may be effective in functional dyspepsia.
14 may warrant an endoscopy, but most will have functional dyspepsia.
15 ural explanation for their symptoms and have functional dyspepsia.
16 biome is another area for future research in functional dyspepsia.
17 ents with gastrointestinal reflux disease or functional dyspepsia.
18  the diagnosis, evaluation, and treatment of functional dyspepsia.
19 e, autoimmune gastritis, gastric cancer, and functional dyspepsia.
20 hich enhance gastric accommodation, to treat functional dyspepsia.
21 iologic targets for ameliorating symptoms of functional dyspepsia.
22 e and postprandial symptoms in patients with functional dyspepsia.
23 ociated with an increased risk of subsequent functional dyspepsia.
24  syndrome (8.3% and 11.4%, respectively) and functional dyspepsia (1.9% and 3.3%, respectively).
25 ents with IBS [4.4%], 2 of 201 patients with functional dyspepsia [1%], and 1 of 311 patients with fu
26 AP-FGD [irritable bowel syndrome = 91(4.9%), functional dyspepsia = 11 (0.6%), abdominal migraine = 3
27  non-infectious enteritis or colitis (7.4%), functional dyspepsia (6%) and ulcers (1.0%).
28 eraction, comprise irritable bowel syndrome, functional dyspepsia, abdominal migraine and functional
29 ed dosing, and long-term safety data: FDACT, Functional Dyspepsia Adherence and Compliance Trial, and
30                                              Functional dyspepsia affects up to 16% of otherwise heal
31 exes more characteristic of diseases such as functional dyspepsia and gastroesophageal reflux disease
32 posite UGI symptoms; trials of patients with functional dyspepsia and gastroparesis; and trials of GE
33  (23 women, 16 men) met Rome II criteria for functional dyspepsia and had no other diagnosis to accou
34 , particularly in subgroups of patients with functional dyspepsia and IBS.
35 fer insight into the pathogenesis of chronic functional dyspepsia and provide a potential model for f
36 h as gastroesophageal reflux disease (GERD), functional dyspepsia and, possibly, pancreatitis.
37 were classified as having IBS, 201 as having functional dyspepsia, and 311 as having functional abdom
38 omes such as irritable bowel syndrome (IBS), functional dyspepsia, and functional chest pain.
39  GERD and those of eosinophilic esophagitis, functional dyspepsia, and gastroparesis, posing a challe
40 rmed only modestly in identifying those with functional dyspepsia, and were not significantly superio
41                         However, symptoms of functional dyspepsia are often worse after a meal, so st
42 eria is allowing recognition of nonulcer (or functional) dyspepsia as an entity that affects a sizabl
43 to compare subsequent incidence of diagnosed functional dyspepsia between adult patients with any dia
44  Our aim was to compare the risk of incident functional dyspepsia between patients with and without s
45 e interval: 2.82 ~ 3.89) increased hazard of functional dyspepsia compared with controls.
46                                     Although functional dyspepsia does not impart any increased risks
47 least $1 billion per year, and patients with functional dyspepsia experience a markedly reduced quali
48 ent study was to determine the prevalence of functional dyspepsia (FD) among patients with hepatitis
49 l disorders; irritable bowel syndrome (IBS), functional dyspepsia (FD) and chronic fatigue (CF).
50      Gastroesophageal reflux disease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (
51  1) the frequency of nausea in patients with functional dyspepsia (FD) and irritable bowel syndrome (
52                       Symptoms suggestive of functional dyspepsia (FD) and irritable bowel syndrome (
53                        Current treatment for functional dyspepsia (FD) has limited and unsustainable
54                                     Although functional dyspepsia (FD) is a common functional gastrod
55                                              Functional dyspepsia (FD) is a functional gastrointestin
56                                              Functional dyspepsia (FD) is a gastrointestinal disorder
57                                              Functional dyspepsia (FD) is associated with anxiety but
58                    It has been reported that functional dyspepsia (FD) is associated with homozygous
59                                 In addition, functional dyspepsia (FD) is characterized by upper abdo
60 ata were included in this study, including 4 Functional dyspepsia (FD) studies, 3 irritable bowel syn
61 pressants are frequently prescribed to treat functional dyspepsia (FD), a common disorder characteriz
62  study was to clarify the pathophysiology of functional dyspepsia (FD), a highly prevalent gastrointe
63 under outpatient conditions in patients with functional dyspepsia (FD), irritable bowel syndrome (IBS
64 , such as Irritable Bowel Syndrome (IBS) and Functional Dyspepsia (FD), significantly impact global h
65 odenal alterations in the pathophysiology of functional dyspepsia (FD), the effect and mechanism of p
66 physiologic abnormalities have been noted in functional dyspepsia (FD), their pathogenesis is poorly
67 r gastrointestinal and systemic symptoms, in functional dyspepsia (FD).
68  risk for irritable bowel syndrome (IBS) and functional dyspepsia (FD).
69 demonstrated symptom relief in patients with functional dyspepsia (FD).
70 tributes to epigastric pain in patients with functional dyspepsia (FD); the etiology and cellular mec
71 tributes to epigastric pain in patients with functional dyspepsia (FD); the etiology and cellular mec
72 ccording to Rome III criteria as having IBS, functional dyspepsia, functional abdominal pain, or abdo
73 ep disorders has been found in patients with functional dyspepsia; however, direction of causality re
74                                  Symptoms of functional dyspepsia, including epigastric pain, early s
75  our understanding of the pathophysiology of functional dyspepsia increases, it is probable that the
76                Patients with peptic ulcer or functional dyspepsia infected by H. pylori were randomiz
77 ders of gut-brain interaction, specifically, functional dyspepsia; irritable bowel syndrome; and chro
78                                              Functional dyspepsia is a heterogeneous disorder involvi
79                                              Functional dyspepsia is a highly prevalent disorder that
80          There are also data to suggest that functional dyspepsia is caused by subtle manifestations
81 mplete understanding of its pathophysiology, functional dyspepsia is difficult to treat and, in most
82 e economic burden of evaluating and treating functional dyspepsia is estimated to be at least $1 bill
83  gastric distention, an important feature of functional dyspepsia, is assessed by stepwise balloon di
84                       The pathophysiology of functional dyspepsia may involve abnormal processing of
85 a specific disorder such as irritable bowel, functional dyspepsia, or abdominal migraine.
86  disorder, such as irritable bowel syndrome, functional dyspepsia, or functional constipation.
87 Twenty healthy controls and 62 patients with functional dyspepsia participated in a gastric barostat
88 c, acotiamide, reduces dyspepsia symptoms in functional dyspepsia patients.
89        Their findings improve treatments for functional dyspepsia patients.
90              A total of 86% met criteria for functional dyspepsia, primarily postprandial distress sy
91                                 Treatment of functional dyspepsia remains a challenge.
92  Adherence and Compliance Trial, and FDSU36, Functional Dyspepsia Safety Update at 36 months.
93                               In adults with functional dyspepsia seen in a tertiary referral practic
94 n in Brazilian patients with peptic ulcer or functional dyspepsia showed no significant difference in
95 ), have been implicated in the generation of functional dyspepsia symptoms.
96 y a normal endoscopy is required to diagnose functional dyspepsia, the utility of endoscopy in all pa
97 standard used to define the presence of true functional dyspepsia was epigastric pain, early satiety
98                                              Functional dyspepsia was found in 66% of the patients (2
99           Although the Rome III criteria for functional dyspepsia were defined 7 years ago, they have
100 owel syndrome, functional abdominal pain, or functional dyspepsia were randomized to 4 weeks of place
101 n therapy should be offered to patients with functional dyspepsia who test positive for Helicobacter
102 e Rome III criteria identified patients with functional dyspepsia with 60.7% sensitivity, 68.7% speci
103 he Rome II criteria identified patients with functional dyspepsia with 71.4% sensitivity, 55.6% speci

 
Page Top